Details for Patent: 6,426,335

Summary for Patent: 6,426,335

Title:	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
Abstract:	This invention discloses a method for preparing a complex comprised of a VEGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a VEGF Nucleic Acid Ligand by SELEX methodology and associating the VEGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more VEGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a VEGF Nucleic Acid Ligand or Complex and methods for making the same.
Inventor(s):	Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO), Schmidt; Paul (Niwot, CO), Vargeese; Chandra (Thornton, CO), Willis; Michael (Louisville, CO)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Application Number:	09/254,968
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 6,426,335

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,426,335

PCT Information
PCT Filed	October 17, 1997	PCT Application Number:	PCT/US97/18944
PCT Publication Date:	May 07, 1998	PCT Publication Number:	WO98/18480

International Family Members for US Patent 6,426,335

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	160821
Austria	256200
Austria	274520
Austria	276266
Austria	315101